FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis

The sBLA is based on results from INSPIRE-I and INSPIRE-II Phase III clinical studies of Ilumya in adults with active psoriatic arthritis. Credit: And-One / Shutterstock.com.